Is Tonix Pharmaceuticals Holding Corp. (TNXP) a Buy, Sell, or Hold?
NASDAQ : TNXP
Tonix Pharmaceuticals Holding Corp.
$12.59 USD
$0.56 (4.66%)
- Volume
- 1.49M
- Average Volume
- 482.82K
- Market Capitalization
- $200.69M
- P/E Ratio
- -0.95
- Dividend Yield
- 0.00%
- Price Target
- $27.00
- Year High
- $69.97
- Year Low
- $9.40
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.61
Company Overview
NASDAQ
Seth Lederman
Biotechnology
Healthcare
TNXP
142
US
USD
Liquidity Metrics
0.01
6.61
6.46
5.72
0.00
Sales & Valuation
$13.11M
6.90
0.86
-1.27
-10.42
Profitability
-$14.57
-$124.02M
-271.18%
-271.18%
-34.10%
-31.06%
P/E Metrics
-0.95
-0.08
-0.08
Analyst Price Target & Rating
$27.00
$27.00
$27.00
3/5
7 Analysts
-53.37%
Financial Health Scores
-2.11
2/9
$177.52M
$257.91M
$30.78M
-$147.39M
Key Metrics (TTM)
$7.59M
0.43
-0.05
6.99
-67.65%
-66.19%
-89.38%
-69.17%
-80 days
Company Executives
| Name | Title |
|---|---|
| Bradley Saenger | Chief Financial Officer & Treasurer |
| Gregory Sullivan | Chief Medical Officer & Secretary |
| Seth Lederman | Co-Founder, President, Chief Executive Officer & Chairman |
| Darryl Rideout | Executive Vice President of Experimental Chemistry |
| Sina Bavari | Executive Vice President of Infectious Disease Research & Development |
| Zeil Rosenberg | Executive Vice President of Medical |
| Mrs. Jessica Edgar Morris | Chief Operating Officer |
| Thomas Englese | Executive Vice President of Commercial Operations |
| Irina Ishak | General Counsel |
| Siobhan Fogarty | Chief Technical Officer |
Poll Results
No votes yet today — be the first to share your view!
About Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Stock
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, w ... hich is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript
2026-08-10 12:58:24
Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript
Tonix Pharmaceuticals Q2 Earnings Call Highlights
2026-08-10 12:06:02
Tonix Pharmaceuticals NASDAQ: TNXP reported second-quarter 2026 net product revenue of approximately $13.5 million, led by $11 million in sales of fibromyalgia treatment Tonmya. The company said Tonmya sales rose 197% from the first quarter, its second full quarter of commercial sales following the product's November launch.
Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
2026-08-10 07:00:00
TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives) First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD) Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study protocol Approximately $176.2 million in cash and cash equivalents as of June 30, 2026 Conference call today at 8:30 a.m. ET BERKELEY HEIGHTS, N.J.
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-08-05 07:00:00
BERKELEY HEIGHTS, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, today announced that the management team will participate in two upcoming investor conferences in August and September 2026.
2026-08-03 07:00:00
Alignment with FDA on key elements of the study design support planned start of the Phase 2 study in the first quarter of 2027
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
2026-07-27 07:00:00
BERKELEY HEIGHTS, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, today announced that it will host a conference call and webcast to report second quarter 2026 financial results and operational highlights on Monday, August 10, 2026, at 8:30 a.m. ET.
2026-07-15 09:05:00
Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003 outbreak
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
2026-07-13 07:00:00
New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the U.S.)
Frequently Asked Questions
-
What is the current Tonix Pharmaceuticals Holding Corp. (TNXP) stock price?
-
Tonix Pharmaceuticals Holding Corp.(NASDAQ:TNXP) stock price is $12.59 in the last trading session. During the trading session, TNXP stock reached the peak price of $69.97 while $9.4 was the lowest point it dropped to. The percentage change in TNXP stock occurred in the recent session was 4.66% while the dollar amount for the price change in TNXP stock was $0.56.
-
TNXP's industry and sector of operation?
-
The NASDAQ listed TNXP is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of TNXP?
-
Bradley Saenger | Chief Financial Officer & Treasurer
Gregory Sullivan | Chief Medical Officer & Secretary
Seth Lederman | Co-Founder, President, Chief Executive Officer & Chairman
Darryl Rideout | Executive Vice President of Experimental Chemistry
Sina Bavari | Executive Vice President of Infectious Disease Research & Development -
How many employees does TNXP have?
-
Number of TNXP employees currently stands at 142. TNXP operates from 200 Connell Drive, Berkeley Heights, NJ 07928, US.
-
Link for TNXP official website?
-
Official Website of TNXP is: https://www.tonixpharma.com
-
How do I contact TNXP?
-
TNXP could be contacted at phone #862 799 8599 and can also be accessed through its website. TNXP operates from 200 Connell Drive, Berkeley Heights, NJ 07928, US.
-
How many shares of TNXP are traded daily?
-
The average number of TNXP shares traded daily for last 3 months was 482.82K.
-
What is the market cap of TNXP currently?
-
The market value of TNXP currently stands at $200.69M with its latest stock price at $12.59